Collaboration to make therapeutic solutions to health challenges


Chiesi Group has signed a memorandum of understanding with Karolinska Institutet (KI) to collaborate on joint efforts aimed accelerating research and development initiatives for respiratory diseases, rare diseases, diseases of prematurity, and other speciality care indications.

Chiesi Group and KI will exchange ideas, expertise, and resources to accelerate the translation of scientific discoveries into tangible healthcare solutions. Their collaboration is underpinned by a shared commitment to advancing medical science and improving patient care through joint research, development, and innovation efforts.

Mark Parry-Billings, Head of Drug Development at Chiesi and Site Head of Chiesi’s R&D operations based in the Karolinska Science Park, said: “We are delighted to advance our work with KI through this collaborative agreement, which will leverage past successes and form a platform for a close and dynamic research and development partnership, in a series of focused scientific disciplines, including for example in the field of translational medicine”.

Åsa Wheelock, Board member of the Chiesi-KI alliance and Head of the Respiratory Medicine Unit, Department of Medicine Solna, at KI said: “This alliance provides an enhanced platform to expand our collaborations beyond our ongoing joint efforts on sub-grouping of patients in the asthma-COPD spectrum. As such, this collaboration underscores Karolinska Institutet’s dedication to translating cutting-edge research into tangible solutions that address the needs of patients worldwide”.

Through this partnership, Chiesi Group and KI are positioned to drive innovation, accelerate scientific discovery, and ultimately improve patient outcomes in areas of high unmet need.

Megan Thomas, Multimedia Editor, DDW

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free